Lilly Asia Ventures
Min Li, Ph.D., is a Venture Partner at Lilly Asia Ventures (LAV). Prior to joining LAV, he was Senior Vice President and Therapeutic Area Head for neurosciences R&D at GSK, and General Manager of R&D China. Prior to GSK, he was a full professor in neuroscience at Johns Hopkins University School of Medicine. He holds a Ph.D. in molecule immunology from Johns Hopkins; received postdoctoral training in neuroscience from University of California San Francisco. He was an undergraduate from Wuhan University.
This person is not in the org chart
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.